MY138319A - 1,5-benzodiazepine derivatives - Google Patents

1,5-benzodiazepine derivatives

Info

Publication number
MY138319A
MY138319A MYPI20001917A MYPI20001917A MY138319A MY 138319 A MY138319 A MY 138319A MY PI20001917 A MYPI20001917 A MY PI20001917A MY PI20001917 A MYPI20001917 A MY PI20001917A MY 138319 A MY138319 A MY 138319A
Authority
MY
Malaysia
Prior art keywords
benzodiazepine derivatives
condations
cck
obesity
formula
Prior art date
Application number
MYPI20001917A
Inventor
David Colclough
Anne Hodgson
Jerzy Ryszard Szewczyk
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910366.5A external-priority patent/GB9910366D0/en
Priority claimed from GBGB0008179.4A external-priority patent/GB0008179D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY138319A publication Critical patent/MY138319A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

AN ENANTIOMERICALLY ENRICHED COMPOUND OF FORMULA (1) IS DISCLOSED PROCESSES FOR ITS PREPARATION , PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND THE USE THEREFORE, FOR THE TREATMENT OF CCK-A MEDIATED DISEASES OR CONDATIONS, SUCH AS OBESITY.
MYPI20001917A 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives MY138319A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9910366.5A GB9910366D0 (en) 1999-05-06 1999-05-06 1,5-Benzodiazepine Derivatives
GBGB0008179.4A GB0008179D0 (en) 2000-04-05 2000-04-05 Chemical process

Publications (1)

Publication Number Publication Date
MY138319A true MY138319A (en) 2009-05-29

Family

ID=26244033

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20001917A MY138319A (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives

Country Status (21)

Country Link
EP (1) EP1212305A2 (en)
JP (1) JP2002544200A (en)
KR (1) KR20020012567A (en)
CN (1) CN1161345C (en)
AR (1) AR022044A1 (en)
AU (1) AU4754800A (en)
BR (1) BR0010338A (en)
CA (1) CA2370801A1 (en)
CO (1) CO5170461A1 (en)
CZ (1) CZ20013988A3 (en)
HK (1) HK1046138A1 (en)
HU (1) HUP0201181A3 (en)
IL (1) IL146124A0 (en)
MX (1) MXPA01011267A (en)
MY (1) MY138319A (en)
NO (1) NO20015397L (en)
NZ (1) NZ515048A (en)
PE (1) PE20010110A1 (en)
PL (1) PL351546A1 (en)
TR (1) TR200103169T2 (en)
WO (1) WO2000068209A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035793A2 (en) * 2003-10-09 2005-04-21 Decode Genetics Ehf. Cckar markers and haplotypes associated with extreme weight conditions
EA010888B1 (en) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Tetraazabenzo[e]azulene derivatives and analogs thereof
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646140A (en) * 1993-04-15 1997-07-08 Glaxo Wellcome Inc. 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646140A (en) * 1993-04-15 1997-07-08 Glaxo Wellcome Inc. 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity

Also Published As

Publication number Publication date
CA2370801A1 (en) 2000-11-16
HK1046138A1 (en) 2002-12-27
HUP0201181A2 (en) 2002-12-28
CN1362949A (en) 2002-08-07
PL351546A1 (en) 2003-05-05
AR022044A1 (en) 2002-09-04
BR0010338A (en) 2002-02-13
WO2000068209A2 (en) 2000-11-16
NO20015397D0 (en) 2001-11-05
IL146124A0 (en) 2002-07-25
PE20010110A1 (en) 2001-03-05
NZ515048A (en) 2004-01-30
NO20015397L (en) 2001-11-05
EP1212305A2 (en) 2002-06-12
WO2000068209A3 (en) 2001-03-01
JP2002544200A (en) 2002-12-24
AU4754800A (en) 2000-11-21
MXPA01011267A (en) 2002-05-06
CZ20013988A3 (en) 2002-02-13
TR200103169T2 (en) 2002-04-22
KR20020012567A (en) 2002-02-16
CO5170461A1 (en) 2002-06-27
CN1161345C (en) 2004-08-11
HUP0201181A3 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
LU91145I9 (en)
PL367682A1 (en) Dolastatin 10 derivatives
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
HK1048990A1 (en) Novel compounds.
AP2000001860A0 (en) Hypolipidemic benzothiazepine compounds.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
PL366198A1 (en) Novel compounds
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
AP9701041A0 (en) Pyridylpyrrole compounds.
HUT72436A (en) Process for the production of imidazopyridines and pharmaceutical compositions containing them and which are suitable for treating gastro-intestinal diseases
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
ZA200110540B (en) Novel diphenyl-piperidine derivate.
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
IL131407A0 (en) Tetrahydropyrido compounds medicaments containing the same and the use thereof
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HK1060558A1 (en) 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof.
GB9907571D0 (en) Compounds
DE69715173D1 (en) Bisarylcyclobutenderivate als cyclooxygenasehemmer
MY114282A (en) Anthracycline derivatives
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
MY138319A (en) 1,5-benzodiazepine derivatives
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
GR3025050T3 (en) Etoposide derivatives, process for their preparation, their use as a drug and in the preparation of a drug for treating cancer.